IL139353A - 1alpha-HYDROXY-25-ENE-VITAMIN D, ANALOGS AND USES THEREOF - Google Patents

1alpha-HYDROXY-25-ENE-VITAMIN D, ANALOGS AND USES THEREOF

Info

Publication number
IL139353A
IL139353A IL13935399A IL13935399A IL139353A IL 139353 A IL139353 A IL 139353A IL 13935399 A IL13935399 A IL 13935399A IL 13935399 A IL13935399 A IL 13935399A IL 139353 A IL139353 A IL 139353A
Authority
IL
Israel
Prior art keywords
1alpha
ene
analogs
vitamin
hydroxy
Prior art date
Application number
IL13935399A
Other languages
English (en)
Other versions
IL139353A0 (en
Original Assignee
Bone Care Internat Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bone Care Internat Inc filed Critical Bone Care Internat Inc
Publication of IL139353A0 publication Critical patent/IL139353A0/xx
Publication of IL139353A publication Critical patent/IL139353A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
IL13935399A 1998-05-29 1999-05-28 1alpha-HYDROXY-25-ENE-VITAMIN D, ANALOGS AND USES THEREOF IL139353A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/087,439 US5972917A (en) 1998-05-29 1998-05-29 1 α-hydroxy-25-ene-vitamin D, analogs and uses thereof
PCT/US1999/012062 WO1999061418A2 (en) 1998-05-29 1999-05-28 1α-HYDROXY-25-ENE-VITAMIN D, ANALOGS AND USES THEREOF

Publications (2)

Publication Number Publication Date
IL139353A0 IL139353A0 (en) 2001-11-25
IL139353A true IL139353A (en) 2005-08-31

Family

ID=22205199

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13935399A IL139353A (en) 1998-05-29 1999-05-28 1alpha-HYDROXY-25-ENE-VITAMIN D, ANALOGS AND USES THEREOF

Country Status (14)

Country Link
US (1) US5972917A (https=)
EP (1) EP1082298B1 (https=)
JP (1) JP2002516307A (https=)
CN (1) CN1238341C (https=)
AT (1) ATE253554T1 (https=)
AU (1) AU754211B2 (https=)
BR (1) BR9910672A (https=)
CA (1) CA2333270A1 (https=)
DE (1) DE69912598T2 (https=)
DK (1) DK1082298T3 (https=)
ES (1) ES2211107T3 (https=)
IL (1) IL139353A (https=)
PT (1) PT1082298E (https=)
WO (1) WO1999061418A2 (https=)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040043971A1 (en) * 1995-04-03 2004-03-04 Bone Care International, Inc. Method of treating and preventing hyperparathyroidism with active vitamin D analogs
US6242434B1 (en) * 1997-08-08 2001-06-05 Bone Care International, Inc. 24-hydroxyvitamin D, analogs and uses thereof
US20020183288A1 (en) * 1995-04-03 2002-12-05 Bone Care International, Inc. Method for treating and preventing hyperparathyroidism
US20020128240A1 (en) * 1996-12-30 2002-09-12 Bone Care International, Inc. Treatment of hyperproliferative diseases using active vitamin D analogues
US20030129194A1 (en) * 1997-02-13 2003-07-10 Bone Care International, Inc. Targeted therapeutic delivery of vitamin D compounds
US6392071B1 (en) * 1997-03-17 2002-05-21 Wisconsin Alumni: Research Foundation 26,27-homologated-20-EPI-2-alkylidene-19-nor-vitamin D compounds
US6087350A (en) 1997-08-29 2000-07-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of pretreatment chemicals to enhance efficacy of cytotoxic agents
AUPP405098A0 (en) * 1998-06-12 1998-07-02 Access Pharmaceuticals Australia Pty Limited Novel methods of preparation of vitamin b12 derivatives suitable for conjugation to pharmaceuticals
ES2250187T3 (es) * 1999-09-20 2006-04-16 Eli Lilly And Company Uso de la hormona paratiroide para reducir el riesgo de cancer.
EP1301479A2 (en) * 2000-07-18 2003-04-16 Bone Care International, Inc. STABILIZED 1$g(a)-HYDROXY VITAMIN D
US6465446B1 (en) * 2001-03-12 2002-10-15 John C. Dykstra Treatment of dermatitis by the topical application of Δ5-androstene-3β-ol-7,17 dione and metabolizable precursors thereof
US7129230B2 (en) 2001-03-12 2006-10-31 Nestec S.A. Method and product for treating cancer in pets
BR0214679A (pt) * 2001-12-03 2004-12-14 Novacea Inc Composições farmacêuticas compreendendo compostos a base de vitamina d ativa
JPWO2003055854A1 (ja) * 2001-12-26 2005-05-12 中外製薬株式会社 ２位に置換基を有するビタミンｄ誘導体
HK1079766B (zh) * 2002-03-29 2007-05-25 威斯康星校友研究基金会 合成1α-羟基-2-亚甲基-19-去甲-高孕钙化醇的方法
US20040053895A1 (en) * 2002-09-18 2004-03-18 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
US7148211B2 (en) * 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
US20040058895A1 (en) * 2002-09-18 2004-03-25 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
BR0315553A (pt) * 2002-10-23 2005-08-23 Leo Pharma As Composto, composição farmacêutica, método de tratamento ou profilaxia de doenças, método de tratamento ou profilaxia de hiperparatireoidismo secundário, e, uso de um composto, opcionalmente em conjunto com outro composto terapeuticamente ativo
WO2004047673A2 (en) * 2002-11-21 2004-06-10 Novacea, Inc. Treatment of liver disease with active vitamin d compounds
JP2007501865A (ja) * 2003-06-11 2007-02-01 ノバセア インコーポレイティッド 放射線治療薬および放射線治療と併用した、活性ビタミンｄ化合物による癌の治療法
WO2004110380A2 (en) * 2003-06-11 2004-12-23 Novacea, Inc. Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
SG110107A1 (en) 2003-09-24 2005-04-28 Bioxell Spa Compound and use in treatment
US7214671B2 (en) * 2004-02-19 2007-05-08 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D3 for the prophylaxis of bone diseases
US7713951B2 (en) * 2004-04-09 2010-05-11 Wisconsin Alumni Research Foundation 2-alkylidene-18,19-dinor-vitamin D compounds
WO2005117542A2 (en) * 2004-05-10 2005-12-15 Novacea, Inc. Treatment of pancreatic cancer with active vitamin d compounds in combination with other treatments
US7094775B2 (en) * 2004-06-30 2006-08-22 Bone Care International, Llc Method of treating breast cancer using a combination of vitamin D analogues and other agents
WO2006113990A2 (en) * 2005-04-25 2006-11-02 Cytochroma Inc. LOW-CALCEMIC 16,23-DIENE 25-OXIME ANALOGS OF 1α ,25-DIHYDROXY VITAMIN D3
DE602006015665D1 (de) * 2005-10-06 2010-09-02 Nestec Sa Probiotische enterokokken für eine verbesserte immunität
US8257948B1 (en) 2011-02-17 2012-09-04 Purecircle Usa Method of preparing alpha-glucosyl Stevia composition
US9386797B2 (en) 2011-02-17 2016-07-12 Purecircle Sdn Bhd Glucosyl stevia composition
US8318459B2 (en) 2011-02-17 2012-11-27 Purecircle Usa Glucosyl stevia composition
US9107436B2 (en) 2011-02-17 2015-08-18 Purecircle Sdn Bhd Glucosylated steviol glycoside as a flavor modifier
US9392799B2 (en) 2011-02-17 2016-07-19 Purecircle Sdn Bhd Glucosyl stevia composition
US20100009949A1 (en) * 2006-03-24 2010-01-14 Bioxell S.P.A. Novel method
EA201691980A1 (ru) 2009-01-27 2017-07-31 БЕРГ ЭлЭлСи Способы уменьшения побочных эффектов, связанных с химиотерапией
CN102655869B (zh) 2009-08-14 2016-08-10 博格有限责任公司 用于治疗脱发的维生素d3及其类似物
US10696706B2 (en) 2010-03-12 2020-06-30 Purecircle Usa Inc. Methods of preparing steviol glycosides and uses of the same
EP2544538B1 (en) 2010-03-12 2022-06-15 PureCircle USA Inc. High-purity steviol glycosides
PT2552484T (pt) * 2010-03-29 2020-04-03 Opko Ireland Global Holdings Ltd Métodos e composições para redução dos níveis de parafróides
US9510611B2 (en) 2010-12-13 2016-12-06 Purecircle Sdn Bhd Stevia composition to improve sweetness and flavor profile
US9029426B2 (en) 2010-12-13 2015-05-12 Purecircle Sdn Bhd Highly soluble Rebaudioside D
WO2014179737A2 (en) 2013-05-03 2014-11-06 The General Hospital Corporation Assays and methods of treatment relating to vitamin d insufficiency
US9052308B2 (en) 2011-01-07 2015-06-09 The General Hospital Corporation Assays and methods of treatment relating to vitamin D insufficiency
EP2661632B1 (en) 2011-01-07 2018-03-07 The General Hospital Corporation Assays and methods of treatment relating to vitamin d insufficiency
MX362676B (es) 2011-02-10 2019-01-31 Purecircle Usa Composición de estevia.
US9474296B2 (en) 2011-02-17 2016-10-25 Purecircle Sdn Bhd Glucosyl stevia composition
DE102011112532B4 (de) 2011-09-05 2019-03-21 Audi Ag Prüfeinrichtung und Verfahren zum Prüfen von Batteriezellen
MX395285B (es) 2012-05-22 2025-03-25 Purecircle Sdn Bhd Glucosidos de esteviol de alta pureza.
US9370527B2 (en) * 2012-12-28 2016-06-21 The Regents Of The University Of Michigan Amelioration of intestinal fibrosis and treatment of Crohn's disease
WO2014194133A1 (en) 2013-05-29 2014-12-04 Berg Llc Preventing or mitigating chemotherapy induced alopecia using vitamin d
JP7572027B2 (ja) 2020-06-30 2024-10-23 国立研究開発法人農業・食品産業技術総合研究機構 セコステロイド構造を有する化合物

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4202829A (en) * 1978-01-05 1980-05-13 Wisconsin Alumni Research Foundation Process for preparing 1α-hydroxylated compounds
US4260549A (en) * 1979-05-21 1981-04-07 Wisconsin Alumni Research Foundation Process for preparing 1α-hydroxylated compounds
US4195027A (en) * 1978-01-16 1980-03-25 Wisconsin Alumni Research Foundation Process for preparing 1α-hydroxylated compounds
US4225596A (en) * 1978-10-13 1980-09-30 Wisconsin Alumni Research Foundation Method for treating calcium imbalance and improving calcium absorption in mammals
JPS5626820A (en) * 1979-08-10 1981-03-16 Chugai Pharmaceut Co Ltd Immunosuppressing agent
US4234495A (en) * 1979-09-10 1980-11-18 Wisconsin Alumni Research Foundation Process for preparing 1α-hydroxyvitamin D compounds from 1α-hydroxy-3,5-cyclovitamin D compounds
EP0028484B1 (en) * 1979-10-23 1985-08-14 Teijin Limited Process for the preparation of active-type vitamin d3 compounds and of the cholesta-5,7-diene precursors, and products so obtained
JPS57149224A (en) * 1981-03-13 1982-09-14 Chugai Pharmaceut Co Ltd Tumor-suppressing agent
US4652405A (en) * 1981-08-28 1987-03-24 Hoffman-La Roche Inc. Synthesis of 1α,25-dihydroxy-24R-fluorocholecalciferol and 1α,25-dihydroxy-24S-fluorocholecalciferol
US4689180A (en) * 1984-01-30 1987-08-25 Wisconsin Alumni Research Foundation 1α,25-dihydroxy-22Z-dehydroxyvitamin D compound
US4481198A (en) * 1984-02-13 1984-11-06 Wisconsin Alumni Research Foundation Vitamin D metabolism inhibitor
US4554106A (en) * 1984-11-01 1985-11-19 Wisconsin Alumni Research Foundation Method for preparing 1α-hydroxyvitamin D compounds
US4555364A (en) * 1984-11-01 1985-11-26 Wisconsin Alumni Research Foundation Method for preparing 1-hydroxyvitamin D compounds
CA1332841C (en) * 1984-11-27 1994-11-01 Noboru Kubodera Vitamin d derivatives and process for producing the same
US4749710A (en) * 1985-05-01 1988-06-07 Hoffmann-La Roche Inc. Immunosuppressive agents
KR0144358B1 (ko) * 1988-04-21 1998-07-15 피. 라이달 크리스텐슨 비타민 d 동족체
US5250523A (en) * 1988-04-29 1993-10-05 Wisconsin Alumni Research Foundation Side chain unsaturated 1α-hydroxyvitanim D homologs
EP0373687B1 (en) * 1988-12-12 1993-06-02 Duphar International Research B.V Method for the photochemical conversion of tachysterol compounds into previtamin d compounds and of trans-vitamin d compounds into cis-vitamin d compounds
US5098899A (en) * 1989-03-06 1992-03-24 Trustees Of Boston University Method for therapeutically treating psoriatic arthritis using vitamin D analogues and metabolites
CA1333616C (en) * 1989-03-09 1994-12-20 Hector F. Deluca 19-nor-vitamin d compounds
GB2229921B (en) * 1989-04-05 1992-12-16 Chugai Pharmaceutical Co Ltd Treatment for hyperparathyroidism with use of vitamin d derivatives
GB8915770D0 (en) * 1989-07-10 1989-08-31 Leo Pharm Prod Ltd Chemical compounds
US5518725A (en) * 1989-09-25 1996-05-21 University Of Utah Research Foundation Vaccine compositions and method for induction of mucosal immune response via systemic vaccination
CA2066716A1 (en) * 1989-09-25 1991-03-26 Raymond A. Daynes Use of steroid hormones in compositions for inducing t cell lymphokine production
US5562910A (en) * 1989-09-25 1996-10-08 University Of Utah Research Foundation Vaccine compositions and method for enhancing an immune response
US5260290A (en) * 1990-02-14 1993-11-09 Wisconsin Alumni Research Foundation Homologated vitamin D2 compounds and the corresponding 1α-hydroxylated derivatives
GB9007236D0 (en) * 1990-03-30 1990-05-30 Leo Pharm Prod Ltd Chemical compounds
EP0454204B1 (en) * 1990-04-27 1995-06-28 Duphar International Research B.V Method for the photochemical isomeration of organic compounds under the influence of a photosensitizer
ATE188482T1 (de) * 1992-02-27 2000-01-15 Duphar Int Res Verfahren zur herstellung 9-beta,10-alpha-5,7- dien-steroiden
DE4220757A1 (de) * 1992-06-24 1994-01-05 Schering Ag Derivate in der Vitamin D-Reihe mit Modifikationen in der 20-Position, Verfahren zu ihrer Herstellung, Zwischenprodukte für dieses Verfahren, diese Derivate enthaltende pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln
GB9220439D0 (en) * 1992-09-28 1992-11-11 Leo Pharm Prod Ltd Chemical compounds
US5753638A (en) * 1992-10-07 1998-05-19 Hoffmann-La Roche Inc. Method of treating hyperproliferative skin disease with Vitamin D3 fluorinated analogs
GB9223061D0 (en) * 1992-11-04 1992-12-16 Leo Pharm Prod Ltd Chemical compounds
US5449668A (en) * 1993-06-04 1995-09-12 Duphar International Research B.V. Vitamin D compounds and method of preparing these compounds
US5665387A (en) * 1994-09-01 1997-09-09 K.U. Leuven Research & Development Methods and compositions for primary and secondary prevention of autoimmune diabetes
US5559107A (en) * 1994-10-20 1996-09-24 Gates; Stephen Regulation of immune response
DK0832063T3 (da) * 1995-06-14 2000-06-13 Schering Ag Vitamin D-derivater med substituenter på C-25, fremgangsmåde til deres fremstilling, mellemprodukter samt deres anvendelse
GB9524812D0 (en) * 1995-12-05 1996-02-07 Leo Pharm Prod Ltd Chemical compounds
US5716946A (en) * 1996-02-13 1998-02-10 Wisconsin Alumni Research Foundation Multiple sclerosis treatment

Also Published As

Publication number Publication date
DK1082298T3 (da) 2004-02-16
CN1303368A (zh) 2001-07-11
AU754211B2 (en) 2002-11-07
IL139353A0 (en) 2001-11-25
JP2002516307A (ja) 2002-06-04
ES2211107T3 (es) 2004-07-01
EP1082298A2 (en) 2001-03-14
WO1999061418A3 (en) 2000-03-23
CN1238341C (zh) 2006-01-25
AU4544599A (en) 1999-12-13
WO1999061418A2 (en) 1999-12-02
PT1082298E (pt) 2004-03-31
CA2333270A1 (en) 1999-12-02
ATE253554T1 (de) 2003-11-15
US5972917A (en) 1999-10-26
DE69912598T2 (de) 2004-09-23
DE69912598D1 (de) 2003-12-11
BR9910672A (pt) 2001-01-30
EP1082298B1 (en) 2003-11-05

Similar Documents

Publication Publication Date Title
IL139353A (en) 1alpha-HYDROXY-25-ENE-VITAMIN D, ANALOGS AND USES THEREOF
IL139355A (en) 24-hydroxyvitamin d, analogs and uses thereof
BG103646A (en) Arylsulphonamides, their analogues and application for the treatment of neurodegenerative diseases
IL159300A0 (en) Prodrugs of gaba analogs, compositions and uses thereof
BR0214838A (pt) Composição para promoção de crescimento ósseo e manutenção da saúde óssea
IL189629A0 (en) Compositions containing human ctla-4 antibodies
CA2207289A1 (en) Supplemented and unsupplemented tissue sealants, methods of their production and use
MXPA03008135A (es) Combinacion de analogos de epotilona y agentes quimioterapeuticos para tratamiento de enfermedades proliferativas.
DE69905170D1 (en) Thiazolopyrimidinderivate
WO2004002415A3 (en) Compositions and methods for modulating a cytotoxic t lymphocyte immune response
AU2002352832A1 (en) 3-alkylated-5,5',6,6',7,7',8,8'-octahydro-2,2'-binaphthols and 3,3'-dialkylated-5,5',6,6',7,7',8,8'-octahydro-2,2'-binaphthols and processes for making them
WO2003013270A3 (en) Calcium dietary supplement
DE69938192D1 (en) Imidazonaphthyridine
GR3032763T3 (en) Branched polysaccharide, microorganism producing it and compositions containing them
AU5870099A (en) Use of diltiazem for treating retinal pathologies
WO2002066068A3 (en) Method of treating neurological diseases
IL140044A0 (en) Compounds with growth hormone releasing properties
GB9516967D0 (en) Pharmaceutical composition
AU1506692A (en) Pharmaceutical compositions
AU2003266960A1 (en) Composition for the treatment of pain, especially for the treatment of articular pain
ATE244230T1 (de) Dihydrobenzofluorenverbindungen, zwischenprodukte,zusammensetzungen und methode
BR0307021A (pt) Uso de alquilfosfocolinas no tratamento preventivo de doenças de protozoários
PL347433A1 (en) Compounds with growth hormone releasing properties
TW447251U (en) Healthy shoes for stimulating human vital points

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees